Amid a bois­ter­ous fundrais­ing week, Bio­Med­Part­ners airs $107M biotech fund

As the VC dol­lars con­tin­ue to dom­i­nate bio­phar­ma head­lines this week, Swiss VC group Bio­Med­Part­ners AG has an­nounced its own wind­fall: it’s raised an ad­di­tion­al $107 mil­lion in new mon­ey for it’s third ven­ture fund.

The firm, which in­vests in pri­vate ear­ly- to mid-stage com­pa­nies, plans to in­vest in 12 to 15 com­pa­nies with the new fund. In fact, af­ter clos­ing on the new cash last month, Bio­Med­Part­ners al­ready made three in­vest­ments: Car­dior Phar­ma­ceu­ti­cals, a Ger­man biotech that’s de­vel­op­ing heart dis­ease ther­a­pies; Amal Ther­a­peu­tics, a Gene­va com­pa­ny de­vel­op­ing can­cer vac­cines; and Al­le­cra Ther­a­peu­tics SAS, a late-stage an­tibi­otics com­pa­ny near Bio­Med­Part­ners’ head­quar­ters in Basel, Switzer­land.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER